Holen Sie sich die Stockscreener-App
46.82
1.01%
0.47
Handel nachbörslich:
46.82
Schlusskurs vom Vortag:
$46.35
Offen:
$46.09
24-Stunden-Volumen:
5.06M
Relative Volume:
1.05
Marktkapitalisierung:
$95.25B
Einnahmen:
$42.06B
Nettoeinkommen (Verlust:
$7.96B
KGV:
13.35
EPS:
3.5062
Netto-Cashflow:
$5.64B
1W Leistung:
+7.14%
1M Leistung:
+8.00%
6M Leistung:
+19.84%
1J Leistung:
+26.64%
1-Tages-Spanne:
$45.99
$47.02
1-Wochen-Bereich:
$45.50
$47.16
52-Wochen-Spanne:
$31.71
$47.16
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
46.82 | 93.15B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
907.68 | 802.41B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
186.86 | 448.76B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
216.04 | 374.44B | 59.64B | 2.37B | 18.24B | 1.331 |
|
NVS
Novartis Ag Adr
|
125.01 | 237.66B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
83.86 | 206.04B | 63.99B | 19.05B | 14.72B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
3 Dividend Stocks for November 2025 - Morningstar
GSK PLC Sponsored ADR (NYSE:GSK) Given Average Rating of "Hold" by Analysts - MarketBeat
Arkadios Wealth Advisors Acquires 6,734 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR Plans Quarterly Dividend of $0.42 (NYSE:GSK) - MarketBeat
Anti-Inflammatory Drugs Market to Reach USD 274.79 Billion by 2034, Fueled by Rising Innovation and Accessibility - GlobeNewswire Inc.
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology - Morningstar
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View - TradingView
ETFs Investing in GSK plc Sponsored ADR Stocks - TradingView
Whittier Trust Co. Sells 5,805 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
GSK plc Sponsored ADR (GSK) Stock Forecast & Price Targets: Today, Tomorrow, Next Week - Traders Union
GSK plc Sponsored ADR (GSK) Stock Price Prediction for 2025, 2026, 2030-2040 - Traders Union
FDA Approves GSK's Withdrawn Blood Cancer Drug Blenrep - Sahm
J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK) - The Globe and Mail
GSK PLC Sponsored ADR $GSK Shares Acquired by Ethic Inc. - MarketBeat
Stanley Laman Group Ltd. Decreases Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
UK Health Agency Recommends GSK-Backed ViiV Healthcare's Apretude As Injectable HIV Treatment - Sahm
The Best Healthcare Stocks to Buy - Morningstar
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential - Sahm
Rep. Val T. Hoyle Sells GSK PLC Sponsored ADR (NYSE:GSK) Stock - MarketBeat
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Recommendation of "Reduce" from Brokerages - MarketBeat
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy - The Globe and Mail
AstraZeneca Upgraded, Home Depot Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Will Glaxo (GSK) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Why GSK (GSK) is a Top Value Stock for the Long-Term - sharewise.com
GSK PLC (GSK) Stock Price, Trades & News - GuruFocus
AnaptysBio Charts Path To Split Into Two Public Companies By 2026 - Sahm
Park Place Capital Corp Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Bought by Farther Finance Advisors LLC - Defense World
GlaxoSmithKline (GSK) Gets a Hold from Barclays - The Globe and Mail
Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK PLC Sponsored ADR $GSK Shares Sold by Clean Yield Group - MarketBeat
The 10 Best Companies to Invest in Now - Morningstar
Amgen Expands US Manufacturing Network Amid New Tariff Policy - Sahm
TD Private Client Wealth LLC Raises Stock Position in GSK PLC Sponsored ADR $GSK - MarketBeat
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Miller Howard Investments Inc. NY Purchases 13,023 Shares of GSK PLC Sponsored ADR $GSK - MarketBeat
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock? - The Globe and Mail
Why GSK (GSK) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Here's Why GSK (GSK) is a Strong Growth Stock - sharewise.com
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.88%
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):